• Valtecne’s consolidated revenue fell 4.5% to EUR 27.07 million in the first nine months ended September 30, 2026.
• Medical revenue declined 8.3% to EUR 19.33 million, reflecting revenue recognition timing under stock-production contracts.
• Industrial revenue rose 6.6% to EUR 7.74 million as the group sought to maximize production capacity utilization.
• Medical remained the core business, accounting for 71.4% of total revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valtecne S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20279-39-2026_TELEBORSA.pdf), on November 10, 2026, and is solely responsible for the information contained therein.